

## FW: Astrazeneca, Marsden collaboration day

---

**From:**

"Clack, Glen" <[REDACTED]>

**To:**

"Malone, Michael D" <[REDACTED]>, "Bowen, Huw D" <[REDACTED]>

**Date:**

Wed, 08 Apr 2009 08:06:47 -0400

---

-----Original Message-----

From: Alastair Greystoke <[REDACTED]>  
Sent: 08 April 2009 12:32  
To: Stefan Hristu; eholmes@Theranos.com; sdigiaimo@theranos.com  
Cc: Caroline Dive; Clack, Glen  
Subject: Astrazeneca, Marsden collaboration day

Dear Stefan and Elizabeth,

AstraZeneca are holding a scientific collaboration day with the Royal Marsden Hospital in early July. I have been asked if it would be possible to present the work we have done in validating the angiogenesis chip. They are obviously keen to see the results with them using the system on patients treated with Recentin. I think the excellent reproducibility we saw in whole blood along with the correlations with the ELISAs in the live study are well worth showing (as well as the lesson we learnt trying to use my plasma samples in the initial validation). Obviously this is an "internal" meeting but I hope you would be happy for me to show the results, which would hopefully help raise the profile of your device at the Marsden

Alastair

---

This email is confidential and intended solely for the use of the person(s) ('the intended recipient') to whom it was addressed. Any views or opinions presented are solely those of the author and do not necessarily represent those of the Paterson Institute for Cancer Research or the University of Manchester. It may contain information that is privileged & confidential within the meaning of applicable law. Accordingly any dissemination, distribution, copying, or other use of this message, or any of its contents, by any person other than the intended recipient may constitute a breach of civil or criminal law and is strictly prohibited. If you are NOT the intended recipient please contact the sender and dispose of this e-mail as soon as possible.